“Amyotrophic Lateral Sclerosis Pipeline Insight, 2024“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Amyotrophic Lateral Sclerosis Market.
The Amyotrophic Lateral Sclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Amyotrophic Lateral Sclerosis Pipeline Report:
Companies across the globe are diligently working toward developing novel Amyotrophic Lateral Sclerosis treatment therapies with a considerable amount of success over the years.
Amyotrophic Lateral Sclerosis companies working in the treatment market are Aeterna Zentaris, GeNeuro SA, ProJenX, QurAlis Corporation, Wave Life Sciences, Revalesio Corporation, AI THERAPEUTICS, CYTOKINETICS, Ionis Pharmaceuticals, and others, are developing therapies for the Amyotrophic Lateral Sclerosis treatment
Emerging Amyotrophic Lateral Sclerosis therapies in the different phases of clinical trials are- AEZS-130, GNK 301, Prosetin, QRL 201, WVE-004, RNS60, AIT-101, Reldesemtiv, ION363, and others are expected to have a significant impact on the Amyotrophic Lateral Sclerosis market in the coming years.
In September 2024, QurAlis Corporation, a clinical-stage biotechnology company focused on developing precision medicines with the potential to transform the treatment of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases, announced today that it has completed dosing for the first participant cohort in its Phase 1 multiple-ascending dose (MAD) clinical trial of QRL-101 (QRL-101-03; NCT06532396). QRL-101 is a first-in-class selective Kv7.2/7.3 ion channel opener designed to address hyperexcitability-induced disease progression in ALS. Kv7.2 is a mis-spliced protein found in sporadic ALS patients.
In June 2024, Woolsey Pharmaceuticals has reported promising results from its Phase IIa study of BRAVYL, showing a significant reduction in neurofilament light chain (NfL) levels and potential clinical benefits for ALS patients. The open-label, single-arm trial, named Rho Kinase Inhibition in Amyotrophic Lateral Sclerosis (REAL), assessed the initial tolerability, safety, and effects of BRAVYL on clinical outcomes and neurodegeneration biomarkers in ALS patients.
In February 2024, Biogen Inc. (Nasdaq: BIIB) announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the marketing authorization of QALSODY® (tofersen) under exceptional circumstances for the treatment of adults with amyotrophic lateral sclerosis (ALS) linked to a mutation in the superoxide dismutase 1 (SOD1) gene. If approved by the European Commission (EC), QALSODY will become the first treatment in the European Union targeting a genetic cause of ALS, also known as motor neuron disease (MND).
Amyotrophic Lateral Sclerosis Overview
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig’s disease, is a progressive neurodegenerative disorder that affects motor neurons in the brain and spinal cord. These neurons are responsible for controlling voluntary muscle movements, and as they deteriorate, muscles weaken and atrophy. ALS leads to symptoms such as muscle weakness, difficulty speaking and swallowing, and eventually respiratory failure. The exact cause is often unknown, though genetic and environmental factors may contribute. There is no cure, but treatments focus on managing symptoms, improving quality of life, and extending survival.
Get a Free Sample PDF Report to know more about Amyotrophic Lateral Sclerosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/amyotrophic-lateral-sclerosis-als-pipeline-insight
Emerging Amyotrophic Lateral Sclerosis Drugs Under Different Phases of Clinical Development Include:
AEZS-130: Aeterna Zentaris
GNK 301: GeNeuro SA
Prosetin: ProJenX
QRL 201: QurAlis Corporation
WVE-004: Wave Life Sciences
RNS60: Revalesio Corporation
AIT-101: AI THERAPEUTICS
Reldesemtiv: CYTOKINETICS
ION363: Ionis Pharmaceuticals
Amyotrophic Lateral Sclerosis Route of Administration
Amyotrophic Lateral Sclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Intra-articular
Intraocular
Intrathecal
Intravenous
Ophthalmic
Oral
Parenteral
Subcutaneous
Topical
Transdermal
Amyotrophic Lateral Sclerosis Molecule Type
Amyotrophic Lateral Sclerosis Products have been categorized under various Molecule types, such as
Oligonucleotide
Peptide
Small molecule
Amyotrophic Lateral Sclerosis Pipeline Therapeutics Assessment
Amyotrophic Lateral Sclerosis Assessment by Product Type
Amyotrophic Lateral Sclerosis By Stage and Product Type
Amyotrophic Lateral Sclerosis Assessment by Route of Administration
Amyotrophic Lateral Sclerosis By Stage and Route of Administration
Amyotrophic Lateral Sclerosis Assessment by Molecule Type
Amyotrophic Lateral Sclerosis by Stage and Molecule Type
DelveInsight’s Amyotrophic Lateral Sclerosis Report covers around 100+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Amyotrophic Lateral Sclerosis product details are provided in the report. Download the Amyotrophic Lateral Sclerosis pipeline report to learn more about the emerging Amyotrophic Lateral Sclerosis therapies
Some of the key companies in the Amyotrophic Lateral Sclerosis Therapeutics Market include:
Key companies developing therapies for Amyotrophic Lateral Sclerosis are – Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, Alector, GSK, NeuroSense Therapeutics, Biogen, Ionis Pharmaceuticals, Brainstorm Cell Therapeutics, Cytokinetics, Astellas Pharma, Apellis Pharmaceuticals, Clene Nanomedicine Biosciences, AL-S Pharma, MediciNova, Seelos Theraputics, Prilenia Therapeutics, AB Science, Eledon Pharmaceuticals, Revalesio Corporation, Biohaven Pharmaceuticals, UCB Pharma, Ra Pharmaceuticals, AI Therapeutics, and others.
Amyotrophic Lateral Sclerosis Pipeline Analysis:
The Amyotrophic Lateral Sclerosis pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Amyotrophic Lateral Sclerosis with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Amyotrophic Lateral Sclerosis Treatment.
Amyotrophic Lateral Sclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Amyotrophic Lateral Sclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Amyotrophic Lateral Sclerosis market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Amyotrophic Lateral Sclerosis drugs and therapies
Amyotrophic Lateral Sclerosis Pipeline Market Drivers
Need for disease-specific treatment options, rising geriatric population, increasing research and developmental activities are some of the important factors that are fueling the Amyotrophic Lateral Sclerosis Market.
Amyotrophic Lateral Sclerosis Pipeline Market Barriers
However, No standard cure for ALS, unknown cause of the disease and other factors are creating obstacles in the Amyotrophic Lateral Sclerosis Market growth.
Scope of Amyotrophic Lateral Sclerosis Pipeline Drug Insight
Coverage: Global
Key Amyotrophic Lateral Sclerosis Companies: Aeterna Zentaris, GeNeuro SA, ProJenX, QurAlis Corporation, Wave Life Sciences, Revalesio Corporation, AI THERAPEUTICS, CYTOKINETICS, Ionis Pharmaceuticals, and others
Key Amyotrophic Lateral Sclerosis Therapies: AEZS-130, GNK 301, Prosetin, QRL 201, WVE-004, RNS60, AIT-101, Reldesemtiv, ION363, and others
Amyotrophic Lateral Sclerosis Therapeutic Assessment: Amyotrophic Lateral Sclerosis current marketed and Amyotrophic Lateral Sclerosis emerging therapies
Amyotrophic Lateral Sclerosis Market Dynamics: Amyotrophic Lateral Sclerosis market drivers and Amyotrophic Lateral Sclerosis market barriers
Request for Sample PDF Report for Amyotrophic Lateral Sclerosis Pipeline Assessment and clinical trials
Table of Contents
1. Amyotrophic Lateral Sclerosis Report Introduction
2. Amyotrophic Lateral Sclerosis Executive Summary
3. Amyotrophic Lateral Sclerosis Overview
4. Amyotrophic Lateral Sclerosis- Analytical Perspective In-depth Commercial Assessment
5. Amyotrophic Lateral Sclerosis Pipeline Therapeutics
6. Amyotrophic Lateral Sclerosis Late Stage Products (Phase II/III)
7. Amyotrophic Lateral Sclerosis Mid Stage Products (Phase II)
8. Amyotrophic Lateral Sclerosis Early Stage Products (Phase I)
9. Amyotrophic Lateral Sclerosis Preclinical Stage Products
10. Amyotrophic Lateral Sclerosis Therapeutics Assessment
11. Amyotrophic Lateral Sclerosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Amyotrophic Lateral Sclerosis Key Companies
14. Amyotrophic Lateral Sclerosis Key Products
15. Amyotrophic Lateral Sclerosis Unmet Needs
16 . Amyotrophic Lateral Sclerosis Market Drivers and Barriers
17. Amyotrophic Lateral Sclerosis Future Perspectives and Conclusion
18. Amyotrophic Lateral Sclerosis Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
